Fulltext

Clinical value of a combined multi-phase contrast enhanced DOPA-PET/CT in neuroendocrine tumours with emphasis on the diagnostic CT component

Veit-Haibach, Patrick ; Schiesser, Marc ; Soyka, Jan ; Strobel, Klaus ; Schaefer, Niklaus ; Hesselmann, Rolf ; Clavien, P.-A ; Hany, Thomas

In: European Radiology, 2011, vol. 21, no. 2, p. 256-264

Zum persönliche Liste hinzufügen
    Titel
    • Clinical value of a combined multi-phase contrast enhanced DOPA-PET/CT in neuroendocrine tumours with emphasis on the diagnostic CT component
    Autor
    • Veit-Haibach, Patrick. Department of Medical Radiology, Division of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, 8091, Zuerich, Switzerland
    • Schiesser, Marc. Department of Surgery, University Hospital Zurich, Zurich, Switzerland
    • Soyka, Jan. Department of Medical Radiology, Division of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, 8091, Zuerich, Switzerland
    • Strobel, Klaus. Department of Medical Radiology, Division of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, 8091, Zuerich, Switzerland
    • Schaefer, Niklaus. Department of Medical Radiology, Division of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, 8091, Zuerich, Switzerland
    • Hesselmann, Rolf. Department of Medical Radiology, Division of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, 8091, Zuerich, Switzerland
    • Clavien, P.-A. Department of Surgery, University Hospital Zurich, Zurich, Switzerland
    • Hany, Thomas. Department of Medical Radiology, Division of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, 8091, Zuerich, Switzerland
    Dokumententyp
    • Postprint
    Sprache
    • Englisch
    Veröffentlicht in
    • European Radiology, 2011, vol. 21, no. 2, p. 256-264. Springer-Verlag
    Andere elektronische Ausgabe
    OAI-PMH-ID
    • oai:doc.rero.ch:320241
    Summary
    Objective: To assess the clinical value of multi-phase, contrast-enhanced DOPA-PET/CT with emphasis on the diagnostic CT component in patients with neuroendocrine tumours (NET). Methods: Sixty-five patients with NET underwent DOPA-cePET/CT. The DOPA-PET, multi-phase CT and combined DOPA cePET/CT data were evaluated and diagnostic accuracies compared. The value of ceCT in DOPA cePET/CT concerning lesion detection and therapeutic impact was evaluated. Sensitivities, specificities and accuracies were calculated. Histopathology and clinical follow-up served as the standard of reference. Differences were tested for statistical significance by McNemar's test. Results: In 40 patients metastatic and/or primary tumour lesions were detected. Lesion-based analysis for the DOPA-PET showed sensitivity, specificity and accuracy of 66%, 100% and 67%, for the ceCT data 85%, 71% and 85%, and for the combined DOPA cePET/CT data 97%, 71% and 96%. DOPA cePET/CT was significantly more accurate compared with dual-phase CT (p < 0.05) and PET alone (p < 0.05). Additional lesion detection was based on ceCT in 12 patients; three patients underwent significant therapeutic changes based on the ceCT findings. Conclusion: DOPA cePET/CT was significantly more accurate than DOPA-PET alone and ceCT alone. The CT component itself had a diagnostic impact in a small percentage but contributed to the therapeutic strategies in selected patients